CatalYm overhauls C-suite

CatalYm GmbH reshaped its C-suite with four new executives as the biotech advances its lead asset, visugromab, toward late-stage development. The company, which is based in Munich and San Francisco, hired Clinton Musil as CFO and CBO, Sujata Rao as CMO, Heike Krupka as chief development officer, and Andrea “Andi” Goddard as chief technology officer to join Scott Clarke, who took over as CEO in January.

Musil, who has worked on multiple IPOs, was most recently president and CFO of Skyhawk Therapeutics Inc. Rao was CMO of Insilico Medicine Inc. Krupka was VP, head of program management for early & late development, oncology, hematology & cell therapy at BMS. Goddard specialized in manufacturing technology and quality at Roche (SIX:ROG; OTCQB:RHHBY) and its Genentech Inc. unit. CatalYm CFO Anne Burger, CMO Eugen Leo and CSO Christine Schuberth-Wagner are departing the company. ...